Email this article 
Open Access
Subscription or Fee Access
Dosage of Prostate Specific Antigen in Prostate Cancer Diagnosis and Follow-Up
(*) Corresponding author
DOI's assignment:
the author of the article can submit here a request for assignment of a DOI number to this resource!
Cost of the service: euros 10,00 (for a DOI)
Abstract
In this paper, two aspects of the measurement of the Prostate Specific Antigen (PSA) will be evaluated; the first one deals with this measurement in order to diagnose Prostate Cancer, according to a specific scale of values of PSA. The PSA dosage measures the blood level of the enzyme. PSA levels below 4 ng/mL are generally considered normal, while levels above 4 ng/mL are considered abnormal (although in men over 65 years levels up to 6.5 ng/mL may be acceptable, depending on the reference parameters of each laboratory). PSA levels between 4 and 10 ng/mL indicate a higher than normal risk of cancer, but the risk itself does not appear to be directly proportional to the level. When the PSA is above 10 ng/mL, the association with the tumor becomes stronger. Moreover, this paper deals with some aspects of the PSA dosage during follow-up moments of the disease.
Copyright © 2019 Praise Worthy Prize - All rights reserved.
Keywords
References
Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J Urol 1999; 162(2): 293-306.
Stamey TA. Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994. Urology 1995; 45(2): 173-84.
Semjonow A, De Angelis G, Oberpenning F, Schmid HP, Brandt B, Hertle L. The clinical impact of different assays for prostate specific antigen. BJU Int 2000; 86(5): 590-7.
Stephan C, Bangma C, Vignati G, et al. 20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers. Int J Biol Markers 2009; 24(2): 65-9.
Stephan C, Kramer J, Meyer HA, et al. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies. BJU Int 2007; 99(6): 1427-31.
Stephan C, Klaas M, Muller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clinical chemistry 2006; 52(1): 59-64.
Mikolajczyk SD, Rittenhouse HG. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. The Keio journal of medicine 2003; 52(2): 86-91.
Sokoll LJ, Wang Y, Feng Z, et al. proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 2008; 180(2): 539-43; discussion 43.
Jansen FH, van Schaik RH, Kurstjens J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010; 57(6): 921-7.
Ceriotti F, Pontillo M, Fasoli L, Dorigatti F. Pre-analytical phase of proPSA measurement and prostate health index calculation. Biochimica clinica 2011; 35(5): 373-6.
Choi YH, Cho SY, Cho IR. The different reduction rate of prostate-specific antigen in dutasteride and finasteride. Korean J Urol 2010; 51(10): 704-8.
Andriole GL, Bostwick D, Brawley OW, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2011; 185(1): 126-31.
Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. The New England journal of medicine 2004; 350(22): 2239-46.
Richardson TD, Oesterling JE. Age-specific reference ranges for serum prostate-specific antigen. Urol Clin North Am 1997; 24(2): 339-51.
Oesterling JE, Cooner WH, Jacobsen SJ, Guess HA, Lieber MM. Influence of patient age on the serum PSA concentration. An important clinical observation. Urol Clin North Am 1993; 20(4): 671-80.
Young SM, Bansal P, Vella ET, et al. Guideline for referral of patients with suspected prostate cancer by family physicians and other primary care providers. Can Fam Physician 2015; 61(1): 33-9.
Grossman DC, Curry SJ, Owens DK, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. Jama 2018; 319(18): 1901-13.
Gion M, Trevisiol C, Rainato G, Fabricio ASC. Circulating Markers in Oncology: Guide to Appropriate Clinical Use: AGENAS; 2016.
Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. Jama 1992; 267(16): 2215-20.
Berger AP, Deibl M, Strasak A, et al. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Urology 2007; 69(1): 134-8.
Schroder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH. Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 2006; 49(3): 460-5; discussion 5.
Wolters T, Roobol MJ, Bangma CH, Schroder FH. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). Eur Urol 2009; 55(2): 385-92.
Etzioni RD, Ankerst DP, Weiss NS, Inoue LY, Thompson IM. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst 2007; 99(20): 1510-5.
Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147(3 Pt 2): 815-6.
Filella X, Fernandez-Galan E, Fernandez Bonifacio R, Foj L. Emerging biomarkers in the diagnosis of prostate cancer. Pharmacogenomics and personalized medicine 2018; 11: 83-94.
Alford AV, Brito JM, Yadav KK, Yadav SS, Tewari AK, Renzulli J. The Use of Biomarkers in Prostate Cancer Screening and Treatment. Reviews in urology 2017; 19(4): 221-34.
Mikolajczyk SD, Catalona WJ, Evans CL, et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clinical chemistry 2004; 50(6): 1017-25.
Guazzoni G, Lazzeri M, Nava L, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012; 61(3): 455-66.
Nicholson A, Mahon J, Boland A, et al. The clinical effectiveness and cost-effectiveness of the PROGENSA(R) prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technol Assess 2015; 19(87): i-xxxi, 1-191.
Tosoian JJ, Druskin SC, Andreas D, et al. Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice. Prostate cancer and prostatic diseases 2017; 20(2): 228-33.
Stattin P, Vickers AJ, Sjoberg DD, et al. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study. Eur Urol 2015; 68(2): 207-13.
Clarke RA, Zhao Z, Guo AY, et al. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PLoS One 2009; 4(3): e4995.
Ploussard G, de la Taille A. Urine biomarkers in prostate cancer. Nature reviews Urology 2010; 7(2): 101-9.
Cui Y, Cao W, Li Q, et al. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Scientific reports 2016; 6: 25776.
Roobol MJ, Schroder FH, van Leeuwen P, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010; 58(4): 475-81.
Schroder FH, Venderbos LD, van den Bergh RC, et al. Prostate cancer antigen 3: diagnostic outcomes in men presenting with urinary prostate cancer antigen 3 scores >/=100. Urology 2014; 83(3): 613-6.
Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310(5748): 644-8.
Leyten GH, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014; 65(3): 534-42.
Skolarus TA, Wolf AM, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014 Jun 10.
doi:10.3322/caac.21234.
Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005 Jul 27;294(4):433-9.
Resnick MJ, Lacchetti C, Bergman J, Hauke RJ, Hoffman KE, Kungel TM, Morgans AK, Penson DF. Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement. J Clin Oncol. 2015 Mar 20;33(9):1078-85.
Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy. JAMA 2005, 294, 433-439.
Thuret R, Massard C, Gross-Goupil M, Escudier B, Di Palma M, Bossi A, de Crevoisier R, Chauchereau A, Fizazi K. The postchemotherapy PSA surge syndrome. Annals of Oncology 19: 1308–1311, 2008.
Philip J. Saylor, Edward D. Karoly, and Matthew R. Smith. Prospective Study of Changes in the Metabolomic Profiles of Menduring Their First Three Months of Androgen Deprivation Therapy for Prostate Cancer, Clin Cancer Res; 18(13) July 1, 2012.
Nancy L. Keating, A. James O’Malley, and Matthew R. Smith. Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer, J ClinOncol 2006 24:4448-4456.
Kelly WK, Scher HI, Mazurmdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993 Apr;11(4):607-15.
Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998 May;16(5):1835-43.
Please send any question about this web site to info@praiseworthyprize.com
Copyright © 2005-2024 Praise Worthy Prize
